Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

From January 2024 and June 2025, the U.S. Food and Drug Administration (FDA) approved 39 in-vitro toxicology testing products through the 510(k). This period marked a significant reshaping of the global market: Chinese companies, driven by rapid product iteration and precise market positioning, surged in the market share. At the same time, the worsening fentanyl crisis in the U.S. fueled an unprecedented demand for fentanyl testing, making it the most competitive and dynamic segment in the field.

Grail has raised $300 million in a Series C financing round that wasoversubscribed, according to the firm.Ally Bridge Group led the round alongwith Hillhouse Capital Group and 6 Dimensions Capital. Blue Pool Capital, ChinaMerchant Securitie

Freenome has initiated a clinical study tohelp bring an AI-Genomics blood test for colorectal cancer to the U.S. market. Freenome is looking to build a diagnostictest that can learn from its mistakes. The South San Francisco, CA- basedcompa